← Back to Search

Beta Blocker

Spironolactone for Lymphoma

Phase 2

Waitlist Available

Led By Joerg Herrmann, MD

Research Sponsored by Mayo Clinic

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline up to 6 months

Awards & highlights

Study Summary

This trial is testing two different drug therapies to see which is more effective in treating heart function changes after cancer treatment.

Eligible Conditions

Lymphoma
Blood Cancers
Breast Cancer
Sarcoma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline up to 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline up to 6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline up to 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Delta change in left ventricular ejection fraction [LVEF])

Secondary outcome measures

Cardiac function recovery rates between group 1 and group 2

Time to recovery of cardiac function between group 1 and group 2

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Group II (pravastatin, spironolactone)Experimental Treatment4 Interventions

Patients receive standard clinical practice therapy as in Group I. Patients also receive pravastatin PO and spironolactone PO for 6 months.

Group II: Group I (carvedilol, lisinopril)Active Control2 Interventions

Patients receive carvedilol orally (PO) and lisinopril orally (PO), up-titrated to maximum tolerated doses as per standard clinical practice for 6 months.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Spironolactone

2005

Completed Phase 4

~7340

Carvedilol

2011

Completed Phase 4

~1410

Lisinopril

2012

Completed Phase 4

~39510

Pravastatin

2010

Completed Phase 4

~11530

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH

13,657 Previous Clinical Trials

40,933,667 Total Patients Enrolled

1,381 Trials studying Lymphoma

382,400 Patients Enrolled for Lymphoma

Mayo ClinicLead Sponsor

3,206 Previous Clinical Trials

3,767,083 Total Patients Enrolled

62 Trials studying Lymphoma

27,943 Patients Enrolled for Lymphoma

Joerg Herrmann, MDPrincipal Investigator - Mayo Clinic

Mayo Clinic

2 Previous Clinical Trials

440 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has Spironolactone been granted authorization by the FDA?

"As a Phase 2 trial, there is some evidence to indicate that Spironolactone may be safe; thus, it has been assigned an estimated safety score of 2."

Answered by AI

What prior experiments have been conducted utilizing Spironolactone?

"Presently, 69 medical trials concerning the effects of Spironolactone are ongoing with 18 being in the third phase. Most research is happening in Charlottesville, Virginia; yet there are 2029 locations where patients can receive treatment for this drug."

Answered by AI

What ailments is Spironolactone most frequently employed to address?

"Spironolactone is frequently administered to treat cardiovascular diseases, such as myocardial infarction and edema. It has also been known to help patients with primary hyperaldosteronism."

Answered by AI

What is the upper limit of individuals participating in this clinical trial?

"Affirmative. Evidence published on clinicaltrials.gov confirms the ongoing recruitment of participants for this experiment, which was initially presented in September 2020 and updated most recently in August 2022. 40 patients will be admitted at a single medical site."

Answered by AI

Is enrollment for this clinical experiment still open?

"Affirmative. Clinicialtrials.gov reports that this study, which was initially posted on September 1st 2020, is currently seeking participants. About 40 individuals must be registered from a single site for the trial to proceed."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial

Joerg Herrmann, MD 2020. "Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04190433.